The multi-kinase inhibitor sorafenib (tradename Nexavar®, Bayer) has been recently approved by the FDA for the treatment of non-resectable hepatocarcinoma and advanced renal carcinoma. Despite its proven survival benefit, sorafenib can lead to important side effects. The aim of this study is the development of a magnetic nanovector able to efficiently and selectively deliver sorafenib toward cancer lesions thanks to a physical guidance mediated by magnetic nanoparticles. Sorafenib and superparamagnetic iron oxide nanoparticles are encapsulated in solid lipid nanoparticles (SLNs), extensively characterized and in vitro tested on the hepatocellular carcinoma cell line HepG2. Obtained results suggest the possibility to prepare stable SLNs able to destroy HepG2 cancer cells through sorafenib cytotoxic effect, and to enhance this effect in a desired area thanks to the magnetically-driven accumulation of the drug.
Journal: TechConnect Briefs
Volume: 3, Biotech, Biomaterials and Biomedical: TechConnect Briefs 2015
Published: June 14, 2015
Pages: 75 - 77
Industry sectors: Advanced Materials & Manufacturing | Medical & Biotech
Topics: Biomaterials, Cancer Nanotechnology